We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Microfluidic Chip Enables Simultaneous Diagnosis of COVID-19 and Influenza Diseases

By LabMedica International staff writers
Posted on 06 Jan 2022
Print article
Image: Multiplexed genetic diagnostic device (Photo courtesy of Toyohashi University of Technology)
Image: Multiplexed genetic diagnostic device (Photo courtesy of Toyohashi University of Technology)

A research team has developed a microfluidic chip that is capable of simultaneous diagnosis of COVID-19 and influenza diseases, by applying the microfluidic chip technologies.

Researchers from the Toyohashi University of Technology (Toyohashi, Japan) and Jikei University School of Medicine (Tokyo, Japan) built a theoretical model that manipulates microfluidic flow with an extremely simple microchannel design and has established an optimal design theory for microfluidic chips. Further, by using the diagnostic device they developed, they performed genetic amplification experiments on four types of infectious diseases, including COVID-19, and demonstrated that multiplexed rapid and simultaneous diagnosis was possible within 30 minutes. The device can be utilized for genetic diagnoses in a range of fields (e.g. agriculture, farming, and fisheries industries, food industry, and health and medical care), not only human infectious diseases. The diagnostic technology can enable anyone, anywhere, any time to detect viral diseases in a rapid, simple, and low-cost way.

The LAMP (Loop-Mediated Isothermal Amplification) method is a genetic test technology. This simple test method does not require an expensive accurate temperature control equipment, etc., in contrast to the widespread PCR test, and can be conducted on site because it allows genetic amplification at a constant temperature for a constant length of time (60 to 65℃, 30 minutes to an hour or so). However, to diagnose multiple types of viruses, the conventional LAMP method entails considerable effort to perform as many preparations of samples and reagents and genetic amplification reactions as the number of analytes, requiring expert knowledge and skills.

Therefore, the research team developed a polydimethylsiloxane (PDMS)-based multiplexed genetic diagnostic device (size: 45mm x 25mm, reaction chamber: 3µL x 5 pieces) by applying the microfluidic chip technology. It autonomously, equally, and accurately dispenses samples and reagent into an array of reaction chambers simply by introducing the liquid, a mixture of an extremely small amount of sample extracted from the analytes and a reagent, into the diagnostic device. By heating the device in warm water (at 60 to 65℃, for 30 minutes to an hour or so), it is capable of simultaneous diagnosis of multiple types of viruses with only one operation (one work process per sample).

The genetic diagnosis result showed that four types of infectious diseases including the COVID-19 (seasonal influenza A, SARS, and influenza H1N1 pdm09) were successfully detected with this diagnosis device. Only the reaction chamber that reacted when a sample containing the gene of each virus was introduced turned sky blue (denoting a positive reaction) after 30 minutes, which means that visual detection is possible.

In addition, to support on-site diagnoses, the team has developed a smartphone app, which automatically diagnoses the reaction as positive or negative based on photographs taken with a smartphone camera. The diagnosis device is capable of easy automatic test result diagnosis (positive or negative), by placing the device after LAMP reaction in a simple LED illumination device and taking photographs with a smartphone. As a result, it is expected that anyone will be able to easily perform the test, anywhere and anytime. In the future, aiming to commercialize the diagnosis device, the research team will develop devices capable of multiplexed rapid diagnosis of variants of the COVID-19 and human infectious diseases for a safe life during and after the COVID-19 pandemic.

Related Links:
Toyohashi University of Technology 
Jikei University School of Medicine 

Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test
Gold Member
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT
New
Urine Control
MassCheck Amino Acid Analysis Urine Controls
New
FAP Immunoassay
Quantikine QuicKit Human FAP ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: RT-QuIC Prion, CSF is the only definitive antemortem clinical test of its kind that doesn’t involve a brain biopsy (Photo courtesy of Mayo Clinic)

CSF Test Distinguishes Prion Disease from Other Causes of Rapidly Progressive Dementia

Rapidly progressive dementias are a category of dementia where patients experience a swift decline from the onset of symptoms to losing functional independence, typically within two years.... Read more

Immunology

view channel
Image: New insights into preterm infant immunity could inform care (Photo courtesy of 123RF)

New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood

Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more

Pathology

view channel
Image: The Results Manager System (Photo courtesy of QuidelOrtho)

Informatics Solution Elevates Laboratory Efficiency and Patient Care

QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.